首页/数据集/Supplementary Table from Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression

Supplementary Table from Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression

Figshare2016-04-01 更新2026-04-28 收录

肝癌免疫联合治疗

靶向信号通路验证

数据链接：

https://figshare.com/articles/dataset/Supplementary_Table_from_Targeting_Androgen_Receptor_AR_IL12A_Signal_Enhances_Efficacy_of_Sorafenib_plus_NK_Cells_Immunotherapy_to_Better_Suppress_HCC_Progression/22508862 数据链接链接失效反馈

官方服务：

资源简介：

primer sequence used in this manuscript

应用场景：

创建时间：

2016-04-01

纳米药物递送

肝癌免疫联合治疗

Aim: Arsenic has excellent anti-advanced liver cancer effects through a variety of pathways, but its severe systemic toxicity forces the need for a safe and effective delivery strategy. Meth

Taylor & Francis Group2024-10-15 更新30

Supplementary Material for: Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study

肝癌免疫联合治疗

中期HCC临床研究

Introduction: Intermediate-stage hepatocellular carcinoma (HCC) presents varying tumor burdens. For patients unsuitable for transcatheter arterial chemoembolization (TACE) due to high tumor burden, re

Figshare2025-06-18 更新00

PD-1 inhibitors improve the efficacy of tyrosine kinase inhibitors combined with transcatheter arterial chemoembolization in advanced hepatocellular carcinoma: a meta-analysis and trial sequential analysis

肝癌免疫联合治疗

临床疗效荟萃分析

This meta-analysis and trial sequential analysis (TSA) aimed to evaluate the efficacy and safety of triple therapy with tyrosine kinase inhibitors (TKIs) combined with transcatheter arterial chemoembo

Figshare2025-03-28 更新00

Supplementary Material for: First-Line Lenvatinib Plus Pembrolizumab for Hepatocellular Carcinoma: Post Hoc Analysis of Japanese Patients From the Phase 3 LEAP-002 Trial

肝癌免疫联合治疗

临床亚组分析

Introduction: The phase 3 LEAP-002 study (NCT03713593) of advanced hepatocellular carcinoma (HCC) suggested improved antitumor activity of lenvatinib plus pembrolizumab versus lenvatinib alone with ma

Figshare2024-11-14 更新10

Supplementary Material for: Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study

肝癌免疫联合治疗

ALBI预后评估

Introduction: Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) vs sorafenib in the Phase III IMbrave150 study. This exploratory analysis

Figshare2023-03-04 更新00

Supplementary Table from Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression

资源简介：

相关数据集